* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Einstein Technologies (Infectious Disease)
Hepatitis C wikipedia , lookup
Tuberculosis wikipedia , lookup
Carbapenem-resistant enterobacteriaceae wikipedia , lookup
Antibiotics wikipedia , lookup
Gastroenteritis wikipedia , lookup
Schistosomiasis wikipedia , lookup
Human cytomegalovirus wikipedia , lookup
Dirofilaria immitis wikipedia , lookup
Hepatitis B wikipedia , lookup
Epidemiology of HIV/AIDS wikipedia , lookup
Diagnosis of HIV/AIDS wikipedia , lookup
Anaerobic infection wikipedia , lookup
Sexually transmitted infection wikipedia , lookup
Clostridium difficile infection wikipedia , lookup
Oesophagostomum wikipedia , lookup
Microbicides for sexually transmitted diseases wikipedia , lookup
Einstein Technologies (Infectious Disease) Senior Einstein Investigator Link to NonProvisional Patent Application C-740 The present invention provides methods for determining a putative Methods for determining antibacterial, the methods comprising determining whether the chemotherapeutic putative antibacterial inhibits GlgE or Rv3032. The present invention agents targeting alpha- also provides the antibacterial, the pharmaceutical composition and William R Jacobs, Jr. glucan pathways and the method of making the antibacterial as well as a method of uses thereof treating a subject infected with a bacterial comprising administration of the antibacterial. US 12/925,633 C-771 Cultures and protocols for diagnosis of toxigenic Clostridium difficile Disclosed are culture media, protocols and kits for diagnosis of toxigenicClostridium difficile , where the culture medium comprises Cooked Meat Medium with glucose; yeast extract; taurocholate; cycloserine; and cefoxitin. Paul Riska US 13/068,682 Selective betaglucuronidase inhibitors as a treatment for side effects of camptothecin antineoplastic agents Compounds, compositions and methods are provided that comprise selective β-glucuronidase inhibitors for both aerobic and anaerobic bacteria, especially enteric bacteria normally associated with the gastrointestinal tract. The compounds, compositions and methods can be for inhibiting bacterial β-glucuronidases and for improving efficacy of camptothecin-derived antineoplastic agents or glucuronidase-substrate agents or compounds by attenuating the side effects caused by reactivation by bacterial β-glucuronidases of glucuronidated metabolites of camptothecin-derived antineoplastic agents or glucuronidase-substrate agents or compounds. Sridhar Mani PCT/US2010/059690 C-809 Methods and assays for treating filoviridae infections Methods and assays for treating a subject with a filovirus infection using an agent that inhibits Niemann-Pick CI (NPCI), VPSII, VPSI6, VPSI8, VPS33A, VPS39, VPS41, BLOCISI, BLOCIS2, GNPTAB, PIKFYVE, ARHGAP23 or FIG4. Methods for screening for an agent that treats and/or prevents infection of a subject with a filovirus, where the methods comprise determining whether the agent inhibits one or more of Niemann-Pick CI (NPCI), VPSII, VPSI6, VPSI8, VPS33A, VPS39, VPS41. BLOCISI, BLOCIS2, GNPTAB, PIKFYVE, ARHGAP23 or FIG4, wherein an agent that inhibits one or more of NPCI, VPSII, VPSI6, VPSI8, VPS33A, VPS39, VPS41, BLOCISI, BLOCIS2, GNPTAB, PIKFYVE, ARHGAP23 or FIG4 is a candidate for treating and/or preventing an infection with a filovirus and wherein an agent that does not inhibit NPCI, VPSII, VPSI6, VPSI8, VPS33A. VPS39, VPS41, BLOCISI, BLOCIS2, GNPTAB, PIKFYVE, ARHGAP23 or FIG4 is not a candidate for treating and/or preventing an infection with a filovirus. Kartik Chandran PCT/US2012/022349 C-914 Methods and compositions are provided for treating HIV infection and for inhibiting HIV infection, and for identifying purinergic receptor antagonists or Panx 1 hemi-channel blockers useful therefor. The invention provides a method of treating a mammalian subject Novel cellular targets for having an HIV infection, or suspected of having been exposed to HIV, hiv infection comprising administering to the mammalian subject an amount of (i) an antagonist of a Panx 1 hemichannel, or (ii) of an inhibitor of a purinergic receptor, effective to inhibit (a) HIV fusion with a target cell, or (b) HIV replication, or (c) HIV entry into a target cell, or two or more of (a), (b) and (c). Joan Berman PCT/US2013/28160 Einstein Reference Number C-783 C-927 C-951 Title of Patent Application Abstract Mycobacterium tuberculosis δesx-3 mutants Isolated mutant Mycobacterium tuberculosis bacteria comprising a deletion in the ESAT-6 gene cluster region 3 (esx-3 region) are provided, as well as compositions comprising such, methods of production thereof and methods of use thereof. Gut barrier dysfunction treatment and prevention Methods are disclosed for treating and preventing gut barrier dysfunction or an illness associated with gut barrier dysfunction in a subject comprising administering to the subject bacterium that produce an indole or an indole metabolite and for identifying compounds and bacteria for use in treatment and prevention of gut barrier dysfunction or an illness associated with gut barrier dysfunction. ***Please note these technologies are representative of the Einstein Intellectual Property Portfolio that are currently published patents/patent applications and available for licensing. For non-published technologies please contact [email protected]. William R Jacobs, Jr. PCT/US2013/040559 Sridhar Mani PCT/US2013/072709 Version March 2016 Einstein Technologies (Infectious Disease) Einstein Reference Number Title of Patent Application Abstract Senior Einstein Investigator C-952 Method to treat or prevent herpesvirus infections Link to NonProvisional Patent Application Methods and compositions are provided for inhibiting or treating a herpesvirus infection in a subject using inhibitors of mammalian Akt. Betsy Herold PCT/US2013/051987 Steven Anthony Porcelli PCT/CA2012/001095 C-989 The present disclosure pertains to antimicrobial compositions for intravenous administration to patients who have experienced a serious brain trauma, to reduce the risk of occurrence of post-trauma Prophylactic microbial infections. The antimicrobial compositions comprise an αcompositions for galacytosylceramide compound and one or more excipients. The management of present disclosure also pertains to the use of α-galacytosylceramide microbial infections in compounds for the manufacture of antimicrobial medicaments for patients with brain injury intravenous administration to patients with serious brain traumas. The present disclosure also pertains to methods for the prophylactic use of the antimicrobial compositions to reduce the risks of occurrence of post-trauma microbial infections. ***Please note these technologies are representative of the Einstein Intellectual Property Portfolio that are currently published patents/patent applications and available for licensing. For non-published technologies please contact [email protected]. Version March 2016